Mirogabalin
Aliases: Tarlige, Ds-5565, Mirogabalin besylate, Mirogabalin monobenzenesulfonate
Summary
Mirogabalin is approved in Japan and several Asian countries for diabetic peripheral neuropathic pain and postherpetic neuralgia. It has higher binding affinity and slower dissociation from Ξ±2Ξ΄-1 subunits compared to pregabalin, potentially offering improved analgesic effects with fewer CNS side effects. Dose adjustments are necessary for renal impairment: 50% reduction for moderate impairment (CrCl 30-60 mL/min) and 75% reduction for severe impairment.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | - | - | - | 30+mg(notrecommended;supratherapeutic)+ |
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 30-60 min | 1-2 hrs | 2-4 hrs | 3-6 hrs |
Tolerance
Tolerance Decay
Tolerance builds with regular use over days to weeks, as with other gabapentinoids; waits of 1β3 weeks after cessation typically reduce tolerance significantly. Crossβtolerance within the class is expected but not complete; data are classβbased and partly anecdotal.
Cross-Tolerances
Effects
- Pain relief
- Physical euphoria
- Muscle relaxation
- Sleep enhancement
- Anxiolytic
- Muscle Relaxant
- Fatigue
- Sedation
- Sedative
- Dystaxia
- Anxiety suppression
- Reduced anxiety
- Cognitive euphoria
- Empathy enhancement
- Sociability enhancement
- Dizziness
- Cognitive dulling
- Motor control loss
- Amnesia
- Thought deceleration
- Increased music appreciation
- Increased libido
- Perception of bodily lightness
- Tactile enhancement
- Appetite enhancement
- Disinhibition
- Dehydration
- Double vision
- Decreased libido
- Dulled perception